<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00003065</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000065736</org_study_id>
    <secondary_id>CPMC-IRB-7919</secondary_id>
    <secondary_id>NCI-V97-1324</secondary_id>
    <nct_id>NCT00003065</nct_id>
  </id_info>
  <brief_title>Topotecan and Paclitaxel in Treating Patients With Recurrent or Metastatic Cancer of the Cervix</brief_title>
  <official_title>Phase II Investigation of Topotecan and Taxol in Patients With Recurrent/Metastatic Cancer of the Cervix</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Herbert Irving Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so&#xD;
      they stop growing or die. Combining more than one drug may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: Phase II trial to study the effectiveness of topotecan and paclitaxel in treating&#xD;
      patients who have recurrent or metastatic cancer of the cervix.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the response, time to progression, disease free survival, and overall survival&#xD;
           of patients with recurrent and/or metastatic cancer of the cervix treated with a&#xD;
           combination of topotecan and paclitaxel.&#xD;
&#xD;
        -  Determine the feasibility and toxicity of this regimen in these patients.&#xD;
&#xD;
      OUTLINE: Patients receive paclitaxel IV over 3 hours on day 1 and topotecan IV over 30&#xD;
      minutes on days 1-5. Filgrastim (G-CSF) is administered on days 6-14. Treatment repeats every&#xD;
      21 days for a minimum of 2 courses in the absence of disease progression or unacceptable&#xD;
      toxicity.&#xD;
&#xD;
      Patients are followed every 3 weeks.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 25 patients will be accrued for this study within 2 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 1997</start_date>
  <completion_date type="Actual">February 2004</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Cervical Cancer</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>filgrastim</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paclitaxel</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>topotecan hydrochloride</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed recurrent, persistent or metastatic cervical carcinoma&#xD;
             (squamous or adenocarcinoma), with no potentially curative standard treatment&#xD;
&#xD;
          -  Measurable disease or evaluable disease&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 to physiological 60&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  ECOG 0-2&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  Greater than 2 months&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  WBC greater than 3000/mm3&#xD;
&#xD;
          -  Platelet count greater than 100,000/mm3&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin less than 1.5 times normal&#xD;
&#xD;
          -  SGOT/SGPT less than 1.5 times normal&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  BUN less than 1.5 times normal&#xD;
&#xD;
          -  Creatinine less than 1.5 times normal&#xD;
&#xD;
          -  Creatinine clearance greater than 50 mL/min&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  Ineligible for other high priority national or institutional study&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  No prior malignancy except nonmelanoma skin cancer&#xD;
&#xD;
          -  No serious medical or psychiatric illness preventing treatment or informed consent&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  Greater than 4 weeks since prior chemotherapy&#xD;
&#xD;
          -  No greater than 2 prior chemotherapy regimens&#xD;
&#xD;
          -  No prior taxane or camptothecin&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  No concurrent hormonal therapy except that required for nondisease related conditions&#xD;
             (e.g., insulin for diabetes)&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  Greater than 4 weeks since prior radiation therapy&#xD;
&#xD;
          -  No concurrent radiation therapy&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  Greater than 4 weeks since prior surgery&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Amy D. Tiersten, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Herbert Irving Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Herbert Irving Comprehensive Cancer Center at Columbia University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Tiersten AD, Selleck MJ, Hershman DL, Smith D, Resnik EE, Troxel AB, Brafman LB, Shriberg L. Phase II study of topotecan and paclitaxel for recurrent, persistent, or metastatic cervical carcinoma. Gynecol Oncol. 2004 Feb;92(2):635-8. doi: 10.1016/j.ygyno.2003.11.019.</citation>
    <PMID>14766258</PMID>
  </results_reference>
  <verification_date>September 2003</verification_date>
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>January 3, 2014</last_update_submitted>
  <last_update_submitted_qc>January 3, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 6, 2014</last_update_posted>
  <keyword>recurrent cervical cancer</keyword>
  <keyword>stage IVB cervical cancer</keyword>
  <keyword>stage IVA cervical cancer</keyword>
  <keyword>cervical squamous cell carcinoma</keyword>
  <keyword>cervical adenocarcinoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Topotecan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

